David Hastings compensation by year
Arbutus Biopharma Summary Compensation Table · all 6 fiscal years held| Component | FY2018 | FY2019 | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $224,000 | $412,000 | $437,100 | $477,000 | $502,000 | $138,613 |
| Bonus | $75,000 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $229,100 | $270,000 | $296,429 |
| Option awards | $1,002,000 | $459,109 | $809,435 | $692,382 | $837,524 | $944,268 |
| Non-equity incentive | $147,200 | $131,840 | $201,066 | $143,100 | $200,800 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $4,667 | $7,301 | $8,934 | $15,224 | $15,522 | $839,052 |
| Total | $1,452,867 | $1,010,250 | $1,456,535 | $1,556,806 | $1,825,846 | $2,218,362 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arbutus Biopharma Corp DEF 14A filed April 14, 2026, accession 0001140361-26-014623, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Arbutus Biopharma Corp filed document, accession 0001140361-26-014623. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2026.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 112,500 | $367,875 | — |
| RSU | 52,667 | $172,221 | — |
| Option | 356,250 | — | $2.40 |
| Option | 10,417 | — | $4.33 |
| Option | 77,187 | — | $2.81 |
| Option | 171,167 | — | $2.90 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Arbutus Biopharma Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Arbutus Biopharma’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Michael McElhaugh | Former Interim President and Chief Executive Officer | $3,578,150 |
| Tuan Nguyen | Chief Financial Officer | $2,416,995 |
| David Hastings · this page | Former Chief Financial Officer | $2,218,362 |
| Lindsay Androski | President and Chief Executive Officer | $1,369,013 |
David Hastings's compensation dossier, Arbutus Biopharma
You have read David Hastings's totals and holdings. The dossier adds each equity grant Arbutus Biopharma disclosed for David Hastings and Arbutus Biopharma's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Arbutus Biopharma compensation record
free company briefThis page is one person within Arbutus Biopharma's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arbutus Biopharma's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arbutus Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ABUS
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.